Nanotechnology has significantly boosted analytical methods capable of visualizing and characterizing materials at the nanoscale, enabling disease monitoring with high precision. These advances have become particularly relevant in biomedical research, where the demand for enhanced diagnostic tools continues to grow. In this context, contrast agents (CAs) have emerged as essential components in modern imaging techniques, driving efforts toward the development of safer, more efficient, and selective diagnostic materials. The growth in the development of CAs reflects the expansion of applications in imaging modalities. Treatment techniques have benefited from nanotechnology innovations in recent decades, while advancements in imaging modalities demonstrate the demand for next-generation CAs with enhanced resolution and sensitivity. Nanomaterials play a central role in this progress, offering high surface area, adjustable porosity, structural stability, and easy functionalization, for drug delivery and disease monitoring. Hybrid nanoparticles, including core-shell systems, clustered architectures, and nanocomposites integrating metallic or magnetic materials with mesoporous silica, zeolites, or metal-organic frameworks (MOFs), allow control of magnetic relaxivity, X-ray attenuation, optical response, and biological interactions. Molecular scale and nanosized materials contribute to improved contrast, targeted delivery, and enhanced biocompatibility in bioimaging. Together, these advances highlight the potential of nanotechnology to transform biomedical diagnostics and disease detection.
Taube et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: